Allergan plc (NYSE: AGN) today confirmed that the Company has received a notice letter dated July 10, 2015 (the “Notice Letter”) from Akorn Pharmaceuticals stating that the U.S. Food and Drug Administration ( FDA ) has received Akorn’s Abbreviated New Drug Application (ANDA) containing a “Paragraph IV” patent certification seeking approval to market a generic version of Allergan’s Restasis® (cyclosporine ophthalmic emulsion) 0.05% product. In addition, Allergan has received communication suggesting that additional ANDAs for generic versions of Restasis® may have been received by the FDA .
Scientific Study Demonstrates That MiMedx Allografts Stimulate Cellular Proliferation And Migration In A Variety Of Adult Stem Cells MARIETTA, Ga., July 15, 2015 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that its latest peer-reviewed scientific study,“Dehydrated Human Amnion/Chorion Membrane Regulates Stem Cell Activity In Vitro,” was electronically published in the Journal of Biomedical Materials Research: Part B – Applied Biomaterials.
DNAnexus and Intel to Deploy High-Performance Next-Gen Sequencing Analysis Software for Precision Medicine Research in the Cloud
MOUNTAIN VIEW, Calif.–(EON: Enhanced Online News)–DNAnexus, the global leader in genome informatics and data management, today announced that it has worked with Intel Corporation, the world’s largest semiconductor company, to deploy elPrep, a high-performance software tool for the preparation of genomic data for large-scale sequence analysis. The first use is by Janssen Research & Development, a division of Janssen Pharmaceutica, which is currently using elPrep in the settings of precision medicine research and clinical applications. It is the mission of Janssen R&D to discover and develop innovative medicines that ease patient’s suffering, and solve the most important unmet medical needs of our time. read more
Malin Announces Investment In UK-based Immunology Company: Immunocore
DUBLIN–(EON: Enhanced Online News)–Malin Corporation plc. (“Malin”), an Irish-based global life sciences company, today announces it has invested $80 million in Immunocore Limited (“Immunocore”), a world-leading biotechnology company developing novel T cell receptor (TCR) based therapies with the potential to treat a variety of cancers, viral infections and autoimmune diseases. Malin will join Woodford Investment Management, Eli Lilly and Company, RTW Funds as well as a number of existing investors in Immunocore in a financing round of $320 million; Europe’s largest ever Series A life sciences financing. Malin’s investment in Immunocore will be financed through its own cash reserves. Adrian Howd, CEO of Malin, and Kelly Martin, Director of Malin, will join the Board of Immunocore.
Provectus Biopharmaceuticals, Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm A-Think Pharmaceutical Co., Ltd Continue Search for Agreement on PV-10 Use in China
KNOXVILLE, Tenn.–(EON: Enhanced Online News)–Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, http://www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company (“Provectus” or the “Company”), announced that it continues to work with Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm A-Think Pharmaceutical Co., Ltd to reach an agreement on PV-10 use in China.read more
PADF and Merck Launch Digital Data Platform on Maternal Mortality
WASHINGTON–(BUSINESS WIRE)–Worldwide, a woman dies every two minutes due to complications from pregnancy or childbirth. In an effort to reduce maternal mortality rates, the Pan American Development Foundation (PADF) partnered with the pharmaceutical company Merck to carry out a two-year initiative in Mexico, Argentina, and Colombia under the Mothers Global Giving program. read more
Anisina Receives Orphan Drug Designation from FDA for Neuroblastoma
US-Australian drug discovery company, Novogen Limited, has received notification from the U.S. Food and Drug Administration (FDA) that its chemotherapy candidate drug, Anisina, has been granted Orphan Drug Designation for neuroblastoma.
Orphan Drug Designation encourages the development of experimental drugs for clinical indications that do not have a high incidence and has been instigated in a number of territories including the U.S, Europe andAustralia.
Immunocore Secures $320 Million (£205 Million) in Europe’s Largest Private Life Sciences Financing OXFORD, England, July 16, 2015 /PRNewswire/ —– Funding to advance proprietary pipeline to build a premier biotech company Immunocore Limited, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, viral infections and autoimmune disease, today announced the completion of a US $320 million (GBP £205 million) private financing round. The oversubscribed round includes new investors, Woodford Investment Management, Malin Corporation plc, Eli Lilly and Company and RTW Investments, as well as a number of new and existing investors in Immunocore.
Novartis malaria treatment Coartem® 80/480mg receives WHO prequalification, enabling greater access for patients Basel, Switzerland, July 16, 2015 – Novartis antimalarial medicine Coartem® 80/480mg today received World Health Organization (WHO) prequalification, making it the first and only high strength (80/480mg) Artemisinin-based Combination Therapy (ACT) antimalarial treatment available for public sector procurement. This new dosage strength*, has the potential to improve malaria management. WHO prequalification of Coartem® 80/480mg now allows for broad-scale public sector procurement, possibly providing access to the treatment to as many as 25 million malaria sufferers across Africa.
Remedium Technologies Receives FDA Clearance for Hemogrip™ Technology to Help Stop Bleeding
COLLEGE PARK, Md., July 15, 2015 /PRNewswire-USNewswire/ — Remedium Technologies, a medical device company and University of Maryland spin-out advancing the standard of care for treating uncontrolled hemorrhage, today announces the 510(k) clearance of its Hemogrip™ Patch by the FDA Hemogrip™ Patch, the company’s lead product, is indicated for use at vascular access sites, where it rapidly controls bleeding that occurs when accessing veins or arteries for various medical treatments and applications.